company_id,name,ticker,legal_name,incorporation_date,sector,sub_sector,industry_classification,hq_city,hq_state,hq_country,regions_operated,founder_names,founding_story_summary,mission_statement,ownership_status,listed_exchange,isin,cik_like,lei_like,fiscal_year_end,employees_2020,employees_2021,employees_2022,employees_2023,employees_2024,employees_2025_ytd,union_presence_pct_2024,remote_work_pct_2024,primary_products,primary_services,core_ip_assets,patent_count_2025,subsidiaries,banking_partners,major_customers,major_suppliers,go_to_market_strategy,pricing_model,primary_cloud_provider,erp_system,crm_system,data_stack,security_certifications,environmental_goals,diversity_goals,esg_policy_summary,risk_register_top3,competitors,regulators,accounting_standard,tax_jurisdictions,transfer_pricing_method,credit_rating_internal,cash_management_policy,treasury_risk_limits,board_size,board_committees,board_independence_pct_2024,auditor,legal_counsel,pr_agency,investor_relations_contact,media_contact,careers_url_placeholder,website_placeholder,status
C014,MicroFluidics Diagnostics,MFLD,MicroFluidics Diagnostics Inc.,2017-07-25,Medical Devices,Point-of-Care Diagnostics & Lab-on-Chip,NAICS 334516; SIC 3826; GICS 35201030,Palo Alto,California,USA,"North America; Europe; Asia-Pacific","Dr. James Chen; Rebecca Liu","Founded by bioengineers to revolutionize point-of-care diagnostics through microfluidics technology enabling rapid accurate testing in resource-limited settings and decentralized healthcare.","To democratize healthcare diagnostics worldwide by delivering lab-quality testing capabilities directly to the point of care through innovative microfluidics solutions.","Private,N/A,N/A,0003456789,549300MFLD789012,December 31,150,280,420,560,720,790,8,64,"FlowDx Point-of-Care Platform; ChipLab Microfluidic Cartridges; DiagStream Analytics Software","Diagnostic testing services; regulatory consulting; custom assay development","Microfluidics chip design; automated sample processing; AI-powered result interpretation",38,"MicroFluidics Europe GmbH (Zurich); MicroFluidics Asia Pte Ltd (Singapore)","Silicon Valley Bank; Credit Suisse","Medisafe Health; Quest Diagnostics; WHO Global Health Initiative","Corning (glass substrates); IDEX Corporation (precision pumps); Borealis CloudWorks (C003) analytics","Direct healthcare provider sales; distributor partnerships in emerging markets; OEM licensing agreements","Device sales + consumable cartridge revenue + SaaS analytics subscriptions","Borealis CloudWorks (C003) for data analytics with AWS backup","Oracle NetSuite","Salesforce Health Cloud","Snowflake; Apache Kafka; TensorFlow; custom diagnostic algorithms","FDA 510k cleared; CE Mark; ISO 13485; CLIA compliant","Carbon-neutral manufacturing by 2028; 95% recyclable device components; green chemistry in assays","50% women in technical leadership by 2030; global health equity programs","ESG framework emphasizes healthcare access equity, environmental sustainability in manufacturing, and ethical AI in diagnostics.","1. FDA regulatory approval delays; 2. Manufacturing scale-up complexity; 3. International market regulatory variations","Abbott Point-of-Care; Roche Diagnostics; Cepheid; Bio-Rad Laboratories","FDA; EU MDR; WHO; CLIA; CAP","US GAAP","USA; Switzerland; Singapore","Comparable Profits Method with medical device sector benchmarks","BBB+ stable (internal)","Maintain 10 months liquidity; 60% cash in US Treasury bills; strict inventory management","Daily VaR $1.5M; max customer concentration 20%; comprehensive product liability insurance","7","Audit; Regulatory & Quality; Compensation; Nominating & ESG","Deloitte","Wilson Sonsini","HealthTech Communications","ir@microfluidics-dx.com","press@microfluidics-dx.com","https://careers.microfluidics-dx.com","https://www.microfluidics-dx.com",Active
